Filing Details

Accession Number:
0001209191-22-047085
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-22 19:21:56
Reporting Period:
2022-08-18
Accepted Time:
2022-08-22 19:21:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1496323 Igm Biosciences Inc. IGMS Pharmaceutical Preparations (2834) 770349194
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1787362 Bruce Keyt C/O Igm Biosciences, Inc.
325 E. Middlefield Road
Mountain View CA 94043
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-18 10,000 $0.93 49,489 No 4 M Direct
Common Stock Disposition 2022-08-18 10,000 $22.54 39,489 No 4 S Direct
Common Stock Acquisiton 2022-08-19 8,700 $0.93 48,189 No 4 M Direct
Common Stock Disposition 2022-08-19 8,700 $22.82 39,489 No 4 S Direct
Common Stock Acquisiton 2022-08-22 6,300 $0.93 45,789 No 4 M Direct
Common Stock Disposition 2022-08-22 6,300 $20.71 39,489 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2022-08-18 10,000 $0.00 10,000 $0.93
Common Stock Stock Option (right to buy) Disposition 2022-08-19 8,700 $0.00 8,700 $0.93
Common Stock Stock Option (right to buy) Disposition 2022-08-22 6,300 $0.00 6,300 $0.93
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
123,756 2023-01-12 No 4 M Direct
115,056 2023-01-12 No 4 M Direct
108,756 2023-01-12 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,013 Indirect See footnote
Footnotes
  1. The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
  2. This transaction was executed in multiple trades at prices ranging from $22.35 to $22.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. This transaction was executed in multiple trades at prices ranging from $22.40 to $23.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. This transaction was executed in multiple trades at prices ranging from $20.50 to $21.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. The shares are held directly by the reporting person's spouse.
  6. The shares subject to the option are vested and exercisable as of the date hereof.